Study details
Enrolling now
Clinical Trial on Agitation in Alzheimer's Dementia
IGC Pharma, LLC
NCT IDNCT05543681ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
164
Study length
about 3.5 years
Ages
60+
Locations
22 sites in FL, LA, MD +6
What this study is about
Researchers are testing whether a new medication, IGC-AD1, helps reduce agitation in people with Alzheimer's disease. The trial will last for 1266 days and involve approximately 164 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IGC-AD1-Active
- 2.Take IGC-AD1-Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Neurology